Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perspective Therapeutics ( (CATX) ) has provided an update.
On April 1, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress across its wholly owned 212Pb-based oncology portfolio, emphasizing its strategy to redefine radiotherapy in solid tumors. The company underscored a secured clinical supply chain, commercial-scale manufacturing build-out and a strong IP estate spanning the radiopharmaceutical value chain.
The presentation detailed three lead clinical programs: VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R and PSV359 targeting FAP-α in solid tumors, all in ongoing Phase 1/2a trials. Early data showed compelling and durable anti-tumor activity with favorable safety and tumor retention profiles, positioning these candidates as potential first-in-class therapies and signaling an important step in the company’s bid to strengthen its competitive standing in radiopharmaceutical oncology, with Phase 1/2 readouts expected in 2026.
The most recent analyst rating on (CATX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held back primarily by very weak financial performance (no current revenue, widening losses, and accelerating cash burn). Offsetting factors include a low-debt balance sheet and positive corporate developments (financing that extends runway and encouraging interim clinical updates), while technicals are modestly supportive and valuation remains unattractive due to losses and no dividend.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on next-generation radioligand therapies for oncology. Its proprietary platform centers on lead-212 (212Pb)-based agents, combining targeted imaging and therapy to treat solid tumors, including neuroendocrine tumors, melanoma and other advanced cancers, supported by end-to-end manufacturing capabilities and a broad intellectual property portfolio.
Average Trading Volume: 3,516,107
Technical Sentiment Signal: Sell
Current Market Cap: $475.1M
For a thorough assessment of CATX stock, go to TipRanks’ Stock Analysis page.